On April 1 2026, Omnicare, a subsidiary of CVS Health, entered into a stalking‑horse asset purchase agreement with GenieRx Holdings LLC, a joint partnership of Milrose Capital LLC and Integro Asset Management LLC (doing business as Integro Healthcare Services). The agreement is the first step in a court‑supervised sale of Omnicare’s assets under its Chapter 11 bankruptcy filing in September 2025.
Omnicare’s bankruptcy was triggered by a $948.8 million False Claims Act judgment and a series of legal and regulatory challenges that led CVS to record impairment charges exceeding $6 billion. The sale is part of CVS’s long‑term strategy to streamline its long‑term‑care pharmacy business, reduce exposure to the skilled‑nursing and assisted‑living pharmacy market, and refocus capital on core health services and retail operations.
Under the court‑supervised process, GenieRx’s agreement sets the minimum price for Omnicare’s assets. Competing bids are due by April 30 2026, and the auction is scheduled for May 5 2026. The stalking‑horse bid is intended to encourage higher offers and maximize the sale value while protecting CVS from inheriting Omnicare’s legal liabilities.
The transaction is expected to generate cash proceeds for CVS and improve its balance sheet by removing a distressed asset that carries significant legal risk. By divesting Omnicare, CVS can allocate capital to its integrated health model, including recent acquisitions such as Oak Street Health and Signify Health, and pursue potential structural changes that separate its retail and insurance businesses.
GenieRx, backed by Milrose Capital’s $2 billion healthcare portfolio and Integro Healthcare Services’ experience in long‑term‑care pharmacy, is positioned to acquire Omnicare’s clinical expertise and customer relationships. The partnership’s interest reflects confidence that Omnicare’s skilled‑nursing and senior‑living pharmacy operations can be integrated into a broader portfolio of health‑care services.
David Azzolina, President of Omnicare, said, "We are making meaningful progress in our court‑supervised process and are pleased to enter into this purchase agreement with GenieRx. GenieRx's interest reflects the strength of Omnicare's clinical expertise, the trust we have earned from the skilled nursing and senior living communities we serve, and the essential role our teams play in supporting high‑quality care for residents. We are grateful for the continued support of our customers and for the dedication of our colleagues, who remain focused every day on serving residents with care and professionalism."
CVS’s broader strategic moves—including the acquisition of Oak Street Health, the partnership with Signify Health, and the ongoing evaluation of a potential retail‑insurance split—underscore the company’s intent to concentrate on high‑growth, high‑margin segments. The Omnicare sale aligns with this trajectory by shedding a legacy business that has been a source of financial and reputational risk.
By isolating Omnicare’s liabilities and removing a distressed asset from its balance sheet, CVS can strengthen its financial flexibility, reduce exposure to future legal claims, and better position itself to invest in integrated health services that drive long‑term value for patients and stakeholders. The sale represents a significant step in CVS’s effort to streamline operations and focus on core competencies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.